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Abstract
Background: Non-genotoxic carcinogens are notoriously difficult to identify as they do not damage DNA directly
and have diverse modes of action, necessitating long term in vivo studies. The early effects of the classic rodent
non-genotoxic hepatocarcinogen phenobarbital have been investigated in the Fisher rat using a combination of
metabolomics and transcriptomics, to investige early stage mechanistic changes that are predictive of longer term
pathology.
Results: Liver and blood plasma were profiled across 14 days, and multivariate statistics used to identify perturbed
pathways. Both metabolomics and transcriptomics detected changes in the liver which were dose dependent,
even after one day of exposure. Integration of the two datasets associated perturbations with specific pathways.
Hepatic glycogen was decreased due to a decrease in synthesis, and plasma triglycerides were decreased due to
an increase in fatty acid uptake by the liver. Hepatic succinate was increased and this was associated with
increased heme biosynthesis. Glutathione synthesis was also increased, presumably in response to oxidative stress.
Liquid Chromatography Mass Spectrometry demonstrated a remodeling of lipid species, possibly resulting from
proliferation of the smooth endoplasmic reticulum.
Conclusions: The data fusion of metabolomic and transcriptomic changes proved to be a highly sensitive
approach for monitoring early stage changes in altered hepatic metabolism, oxidative stress and cytochrome P450
induction simultaneously. This approach is particularly useful in interpreting changes in metabolites such as
succinate which are hubs of metabolism.
Background
Non-genotoxic carcinogens are difficult to screen for as
the development of tumours only occurs after long term
exposure and, since there is no damage to DNA, they
cannot be detected by conventional genotoxicity assays
such as the Ames test, in vitro clastogenesis assays or
the mouse micronucleus test. Definitive characterization
of non-genotoxic rat carcinogens requires the outcome
of a two year bioassay. There are earlier indicators of
hepatocarcinogenic potential which include increased
liver weight, evidence of cytotoxicity, enzyme induction
and CAR agonist activity which are used to aid dose set-
ting for long term bioassays and in estimating risk.
However, their predictive power is limited and
complicated by the fact that non-genotoxic carcinogens
represent a diverse range of mechanisms [1,2].
Phenobarbital (PB) is a well characterized rodent non-
genotoxic carcinogen which causes an increase in the
incidence of liver tumors after long term exposure. This
follows a reversible increase in liver weight, attributed to
a combination of hyperplasia and hypertrophy [3,4]. In
Fischer F344 rats exposed to PB in the diet for two years,
an increase in the incidence of neoplastic nodules was
reported at a dose of 1000 ppm [5], with no changes
observed at 500 or 600 ppm [6,7]. In another study Rossi
et al. found an increase in adenomas in Wistar rats
exposed to 500 ppm PB in drinking water following
exposure for three years [8]. Isenberg et al. reported that
in F344 rats, exposure to 500 ppm PB in the diet for 1-2
weeks produces an increase in relative liver weight which
is reversible on returning the animals to control diet. If
the exposure is continued for 18 months, then a
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sustained increase in relative liver weight is observed.
However, the increase in liver weight is only accompa-
nied by a transient increase in DNA synthesis, peaking at
two weeks of exposure and no hepatic cancer [9].
With the advent of global profiling approaches, includ-
ing transcriptomics, proteomics and metabolomics, there
is now the opportunity to profile different levels of orga-
nization of a biological system in tissues and biofluids,
thus aiding the understanding of mechanisms/modes of
action and the identification of potential biomarkers of
responses which reflect underlying pathophysiological
perturbations. In addition these ‘omic’ approaches are
hypotheses generating and are particularly appropriate
for systems where the mechanism of toxicity is unknown
or poorly defined [10-12]. Furthermore, profiling a range
of potential biomarkers may provide more sensitive or
earlier indicators of pathological change.
In the present study a combination of metabolomics,
transcriptomics and histology were used to identify
changes occurring in the liver and plasma of Fisher
F344 rats during exposure to a range of doses of PB
over a period of 14 days. The doses were selected to
provide a low dose of 50 ppm which is non-carcinogenic
and does not cause an increase in liver weight, a middle
dose of 500 ppm which causes an increase in liver
weight but is not carcinogenic and high dose of 1000
ppm which is carcinogenic and causes an increase in
liver weight. The integration of data from different
‘omic’ techniques presents a considerable challenge, but
by combining datasets as part of a data fusion process,
it is possible to produce information of greater value
than that obtained from the individual datasets. This
study demonstrates how this data fusion can be
achieved in order to enhance understanding of the
mechanisms involved in a toxic response.
Results
Liver and body weight
There was a significant increase in liver weight (adjusted
for body weight) in PB treated animals compared to
controls (table 1) at all time points for 500 and 1000
ppm. Body weight was significantly increased in the 500
and 1000 ppm groups at day 14 (p < 0.01), reflecting an
increase in the average food intake for the 500 and 1000
ppm groups (10%and 11%, respectively; p < 0.01).
Histopathology
Centrilobular hepatocyte hypertrophy was observed in all
dose groups. The incidence and time of onset were related
to dose. On day 1, only the mid dose (3/5) and high doses
(1/5) were affected, whilst by day 3 the incidence had risen
to 3/5 at 50 ppm, 5/5 at 500 ppm and 1000 ppm. Electron
microscopy confirmed the hypertrophy to reflect smooth
endoplasmic reticulum proliferation (figure 1).
Table 1 Liver and body weights, Ki67 labeling indices
and plasma clinical biochemistry
Dose PB
Control 50 ppm 500
ppm
1000
ppm
Day
1
Relative liver weight
(%)
4.57 ±
0.17
4.67 ±
0.12
4.89 ±
0.09**
4.58 ±
0.15
Body weight (g) 205.8 ±
3.6
207.0 ±
6.9
210.2 ±
9.0
207.2 ±
8.8
Ki67 labeling index
(%)
6.77 ±
2.54
8.63 ±
2.56
7.94 ±
2.41
9.87 ±
2.88
Total Protein (g/l) 62.9 ±
1.1
62.7 ±
1.7
63.9 ±
1.8
62.8 ±
2.0
Cholesterol (mmol/l) 1.39 ±
0.06
1.35 ±
0.08
1.41 ±
0.11
1.39 ±
0.12
Triglycerides (mmol/
l)
1.27 ±
0.26
1.20 ±
0.07
1.56 ±
0.17
1.40 ±
0.44
Alkaline Phosphatase
(IU/l)
1120 ±
27
1071 ±
35
1117 ±
103
1048 ±
106
Glutamate
Dehydrogenase (U/l)
5.56 ±
0.48
6.62 ±
1.29
6.62 ±
1.55
5.64 ±
0.61
Day
3
Relative liver weight 4.73 ±
0.25
4.97 ±
0.21
5.17 ±
0.27*
5.63 ±
0.21**
Body weight (g) 216.4 ±
10.4
214.8 ±
11.6
217.0 ±
7.8
209.0 ±
12.2
Ki67 labeling index
(%)
6.92 ±
0.73
6.14 ±
0.74
9.65 ±
0.58**
11.13 ±
1.73**
Total Protein (g/l) 63.7 ±
3.7
62.9 ±
0.6
63.6 ±
3.6
64.8 ±
3.6
Cholesterol (mmol/l) 1.38 ±
0.09
1.52 ±
0.15
1.72 ±
0.14*
1.86 ±
0.34**
Triglycerides (mmol/
l)
1.27 ±
0.17
1.29 ±
0.35
1.36 ±
0.25
1.33 ±
0.42
Alkaline Phosphatase
(IU/l)
1125 ±
112
1081 ±
38
942 ±
142
864 ±
133**
Glutamate
Dehydrogenase (U/l)
6.28 ±
0.53
5.43 ±
0.36
5.54 ±
0.94
5.82 ±
0.79
Day
7
Relative liver weight 4.31 ±
0.13
4.66 ±
0.12**
5.37 ±
0.17**
5.7 ±
0.14**
Body weight (g) 225.6 ±
4.7
229.8 ±
12.1
228.8 ±
8.3
231.4 ±
6.7
Ki67 labeling index
(%)
5.08 ±
0.33
4.33 ±
1.12
4.63 ±
1.12
4.35 ±
1.21
Total Protein (g/l) 61.0 ±
0.8
61.5 ±
1.1
64.3 ±
1.7**
66.3 ±
1.7**
Cholesterol (mmol/l) 1.44 ±
0.10
1.41 ±
0.12
1.74 ±
0.07**
1.92 ±
0.08**
Triglycerides (mmol/
l)
1.04 ±
0.28
1.26 ±
0.11
0.90 ±
0.26
0.85 ±
0.07
Alkaline Phosphatase
(IU/l)
1007 ±
60
986 ± 95 883 ±
48*
837 ±
51**
Glutamate
Dehydrogenase (U/l)
4.70 ±
0.12
5.78 ±
0.43*
6.26 ±
0.79**
6.64 ±
0.52**
Day
14
Relative liver weight 4.22 ±
0.16
4.43 ±
0.18
5.39 ±
0.23**
5.7 ±
0.16**
Body weight (g) 232.2 ±
7.8
240.6 ±
6.5
258.0 ±
11.4
266.2 ±
13.7
Ki67 labeling index
(%)
2.03 ±
1.04
1.10 ±
0.26
1.38 ±
0.49
1.83 ±
0.63
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Clinical chemistry
Significant changes in plasma clinical chemistry were
only detected with the 500 and 1000 ppm dose groups,
with the exception of glutamate dehydrogenase where
changes were also detected for the 50 ppm dose group.
Plasma cholesterol and alkaline phosphatase activity
were increased on days 3, 7 and 14. Triglycerides were
decreased on day 14 and glutamate dehydrogenase was
increased at day 7. Total protein was increased on days
7 and 14 (table 1).
Labeling Index (Ki67)
At day 3 the Ki67 labeling indices were statistically sig-
nificantly increased by doses of 500 (39%) and 1000
ppm (61%) (table 1). There was no change in the label-
ing index at other time points.
Metabolomic analysis of liver tissue
Principal Components Analysis (PCA) of the 1H nuclear
magnetic resonance (NMR) spectroscopy dataset from
all time points combined demonstrated some separation
according to dose (data not shown). However, analysis
of individual time points using PCA demonstrated
separation between the different dose groups which was
improved by using partial least squares (PLS) to regress
metabolic profile against dose of PB (Q2 = 0.69, 0.54,
0.60, 1 component, for days 1, 3, and 14 respectively, Q2
= 0.60, 2 components, day 7; figure 2A, table 2). The
largest change associated with these PLS plots was a
dose dependent decrease in glucose and glycogen at all
time points in rats exposed to PB. There was also an
increase in succinate and a decrease in adenosine with
increasing dose of PB at all time points. At days 1-7, PB
caused an increase in glutamine and glutathione (see
additional file 1).
At each time point PCA of the data produced by GC-MS
(gas chromatography-mass spectrometry) analysis of the
aqueous phase separated the different doses of PB,
although at days 1 and 3 the 50 ppm dose group could
not be separated from the control group. The same trend
was also detected using PLS to regress metabolic profile
against dose with improved separation (Q2 = 0.50, 0.55,
0.73, 0.64, all 1 component, days 1, 3, 7 and 14, respec-
tively; figure 2B, table 2). PB caused an increase in succi-
nate and glycine at all time points and 5-oxoproline at
days 1, 3 and 14. Disaccharides, ethanolamine and fruc-
tose were also all decreased by PB at days 1, 3 and 7 and
ribose was decreased at days 3 and 14 (table 3).
While there was no dose dependent trend in the data
from the lipid fraction detected by PCA or PLS at day 1,
at days 3, 7 and 14 there was separation according to
dose with the same trend being detected at each time
point. By PCA there was some separation between the
control and 50 ppm groups and the 500 and 1000 ppm
groups which was increased by PLS but the control
group and 50 ppm dose group were still poorly discrimi-
nated, as were the 500 and 1000 ppm dose groups (Q2 =
0.43, 0.55, 0.41, all 1 component, days 3, 7 and 14
respectively; figure 2C, table 2). These models deter-
mined that PB caused an increase in oleic acid at days
3, 7 and 14 and an increase in cis-5,8,11,14,17-eicosa-
pentaenoic acid at days 7 and 14. At days 3 and 7 PB
caused a decrease in arachidonic acid, docosahexaenoic
acid and pentadecanoic acid (table 3). The PLS models
built for each technique and time point all passed cross-
validation either in terms of predicting the dose of PB
during a leave-one-out analysis (figure 2d) or during a
random permutation test for dose (figure 2e).
High resolution magic angle spinning 1H NMR analysis of
liver tissue
Following the observation that PB exposure decreased
the glucose and glycogen content of the liver, we
hypothesized PB alters the ratio of mobile cytosolic lipid
to carbohydrate in the liver. High resolution magic
angle spinning (HRMAS) NMR spectroscopy is a techni-
que which allows the acquisition of high resolution
NMR spectra from solid tissue samples, and was con-
ducted on intact liver samples from day 14 to determine
if the ratio of lipid to carbohydrate in the liver was
changed by PB exposure. PLS separated the 0 and 50
ppm groups from the 500 and 1000 ppm groups (Q2 =
0.86, 4 components) (figure 2f). The loadings showed
that resonances corresponding to the fatty acids and
choline groups of lipids were increased with increasing
dose of PB, whereas resonances from glucose and glyco-
gen were decreased with increasing dose of PB (figure
2g). The ratio of total fat to total carbohydrate increased
by 103% and 134% for the 500 and 1000 ppm groups,
respectively (p < 0.01) (figure 2h).
Metabolic profiling of plasma
PCA of data from individual time points from the 1H-
NMR spectroscopy of the blood plasma samples sepa-
rated the control and 50 ppm dose groups from the 500
and 1000 ppm dose groups for all time points after day 1,
with this separation becoming more pronounced at 7 and
Table 1: Liver and body weights, Ki67 labeling indices and
plasma clinical biochemistry (Continued)
Total Protein (g/l) 60.9 ±
0.9
59.8 ±
1.5
64.5 ±
1.9*
65.3 ±
3.2**
Cholesterol (mmol/l) 1.22 ±
0.07
1.14 ±
0.10
1.42 ±
0.13*
1.60 ±
0.17**
Triglycerides (mmol/
l)
1.15 ±
0.11
1.23 ±
0.20
0.68 ±
0.10**
0.53 ±
0.14**
Alkaline Phosphatase
(IU/l)
952 ±
55
889 ±
149
821 ± 39 765 ±
14**
Glutamate
Dehydrogenase (U/l)
5.76 ±
1.26
6.56 ±
2.37
5.06 ±
0.86
6.92 ±
0.86
Relative liver weight, body weight, Ki67 labeling index and plasma clinical
biochemistry data (for parameters which were significantly changed). All
values are mean ± standard deviation. * p < 0.05 compared to time matched
controls, ** p < 0.01 compared to time matched controls.
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14 days (PLS models Q2 = 0.35, 0.68, 1 component, days
3 and 14 respectively, Q2 = 0.61, 2 components, day 7;
figure 3A, table 2). The concentrations of valine, lactate,
glutamate and glutamine were increased by PB exposure
at days 3, 7 and 14. Similarly, the concentrations of iso-
leucine, leucine acetate and choline/phosphocholine were
increased at days 7 and 14. PB caused a decrease in
plasma lipid which was more pronounced at later time
points (table 3). The broad resonance corresponding to
the terminal methyl groups of fatty acids changed in
Table 2 Q2 values for PLS models
NMR
aqueous
GC-MS
aqueous
GC-MS lipid Plasma
NMR
Day 1 0.69 (1) 0.50 (1) - -
Day 3 0.54 (1) 0.55 (1) 0.43 (1) 0.35 (1)
Day 7 0.50 (2) 0.73 (1) 0.55 (1) 0.61 (2)
Day 14 0.60 (1) 0.64 (1) 0.41 (1) 0.68 (1)
Q2 values for PLS models using data from different platforms and at different
time points. The Q2 is a measure of how robust a model is, scored out of 1,
with higher values indicating a better model. The number in brackets is
number of components in the model.
Figure 1 Liver histopathology. Liver histology. Upper panel: light microscopy image of hematoxylin and eosin stained liver tissue from control
(A) and PB treated (B) animals. Livers from PB treated animals show centrilobular hypertrophy, compression of the periportal areas and
eosinophilc appearance. Lower panel: electron microscopy images of control (C) and PB treated livers (D, E & F). PB treated livers showed
dispersion of organelles and proliferation of the smooth endoplasmic reticulum.
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Figure 2 PLS modeling of metabolomic data. PLS plots correlating metabolic profiles with dose of PB at day 14 using 1H-NMR (A), GC-MS
analysis of the aqueous extract (B), and GC-MS analysis of the lipid extract (C). In addition to the use of Q2 values, models were validated to
prevent over fitting by leaving samples out of the model building stage and then predicting their dose of PB (D) (mean ± standard deviation of
5 iterations) and also by using the validate function in SIMCA-P+ with 200 iterations (E). In this approach the actual model is compared with
models formed where the Y value (in this case dose) is randomly permuted to produce models where there should be no correlation between
the X-block and Y-block matrices. As demonstrated in panel E, the decreases in R2 and Q2 as the dose is randomly permuted is indicative of a
robust model. PLS analysis of MAS 1H-NMR data separated the control and low dose from the mid and high dose groups (F). The corresponding
loadings column plot (G i) and assigned spectra (G ii) showed that exposure to PB increased lipids and decreased sugars. The ratio of total lipid
to total carbohydrate was increased in the mid and high dose groups compared to the control group (H). Plot show average ± standard
deviation (n = 5) with significant changes as determined by ANOVA with Dunnett’s post test for multiple comparisons labelled ** (p < 0.01). Key:
Control (filled square) 50 ppm (open circle) 500 ppm (filled triangle) 1000 ppm (open circle).
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shape with an increase in the 0.84-0.86 ppm region and
decrease in the 0.88-0.90 ppm region (figure 3B), reflect-
ing an increase in the fraction of higher density lipopro-
teins [13].
Gene expression profiling of liver
Phenobarbital induced changes in the expression of 897
probesets. Hierarchical clustering using Pearson correla-
tion coefficients revealed a complex temporal and dose-
dependent pattern (figure 4). Some genes were clearly
upregulated transiently at early time points (figure 4A
and 4B), whereas others showed persistent down- or up-
regulation (figure 4C and 4D respectively). Those genes
showing transient increases in expression were over-
represented in Gene Ontology, KEGG and GenMAPP
annotations associated with the proteosome, starch and
sucrose metabolism and the cell cycle. Those genes that
have sustained alterations in expression were over-repre-
sented in genes with annotations including control of
apoptosis, oxidative stress, and xenobiotic metabolism
(additional file 2).
Integration of metabolomic and transcriptomic data
Two approaches were taken to integrate the data gener-
ated by metabolomic and genomic analyses. Firstly, sig-
nificant changes in gene expression were mapped on to
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
metabolic pathways using GeneSpring (Agilent Technol-
ogies, Santa Clara, CA). This allowed the identification
of pathways where both the expression of transcripts
and concentration of metabolites were altered by PB. In
this way an association between the decrease in hepatic
glycogen and a decrease in glucokinase (hexokinase D)
on the glycogen synthesis pathway was identified (fig-
ures 5A and 5B, table 3). This approach also identified a
Table 3 Fold change in expression of selected genes.
Fold change relative to time matched controls
Time point Day 1 Day 3 Day 7 Day 14
Dose (ppm) 50 500 1000 50 500 1000 50 500 1000 50 500 1000
hexokinase D 1.10 0.67 0.23* 0.99 0.84 0.41 0.85 0.30* 0.39* 0.64 0.44* 0.40
glutamine synthetase 1.09 0.60** 0.57** 0.83 0.48** 0.39** 1.01 0.46* 0.45** 0.80* 0.44** 0.30*
glutamine cysteine ligase 1.00 1.28 1.59* 1.11 1.76** 1.80** 0.64** 0.69** 0.92 1.06 1.16 1.04
glutathione reductase 1.14 1.30* 1.57** 1.16 1.86** 1.99** 0.79 1.33** 1.74** 0.94 1.43 1.61*
malic enzyme 1.38 1.84** 1.72* 0.77 1.64* 1.87** 0.87 1.13 1.71 1.19 2.15* 1.74
aminolevulinate synthase 1.84 2.54* 3.68** 1.06 1.77* 2.29** 1.26 1.54 2.05 0.83 1.40 1.39
lipoprotein lipase 0.83* 0.95 1.19 1.13 1.69 2.32** 1.13 3.94** 7.33** 0.81 4.19** 5.16**
epoxide hydrolase 1.36* 2.19** 2.57** 1.14 2.46** 2.88** 1.15 2.38** 2.67** 1.72* 3.33** 3.33**
CYP 3A 3 1.21 1.66** 1.74** 0.97 1.71** 1.84** 1.02 1.69** 1.70** 1.04 1.58** 1.81**
Aldehyde dehydrogenase 1 A1 1.41 2.69* 4.87** 1.28 6.09* 9.82** 1.31 8.70** 14.11** 3.93 23.86** 24.59**
liver UDP-glucuronosyltransferase, PB-
inducible form
1.88 3.96** 4.98** 2.77** 6.45** 6.71** 3.97** 6.18** 6.63** 3.63** 6.10** 5.89**
glutathione S-transferase Yb4 gene 0.91 1.73 2.19 1.65 6.27** 9.01** 1.45 6.19** 8.44** 1.80 6.56** 7.89**
CYP 2B2 4.23* 7.30** 7.06** 5.74** 8.75** 9.16** 5.58** 8.08** 7.01** 6.19** 8.48** 8.71**
Fold changes in expression for selected genes. * p < 0.05 compared to time matched controls, ** p < 0.01 compared to time matched controls.
Figure 3 Plasma lipoprotein profile. PLS plots correlating
metabolic profiles with dose of PB at day 14 using 1H-NMR
spectroscopy of blood plasma (A). Key: Control (filled square), 50 ppm
(open circle), 500 ppm (filled triangle), 1000 ppm (open square).
Overlaid 1H-NMR spectra from the region containing the terminal
methyl group of fatty acids in blood plasma (B). A change in the
shape of the peak, with an increase in the proportion of lower
chemical shift, higher density lipoprotein with increasing dose of PB
is clearly detected. This is characteristic of an increase in high density
lipoprotein particles relative to low density lipoprotein particles.
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Figure 4 Hierarchical clustering of transcriptomic data. Hierarchical clustering using Pearson correlation coefficients revealed different
temporal patterns of gene expression changes due to exposure to phenobarbital. Some genes were transiently upregulated at early time points
(A &B), whereas others showed a sustained decrease (C) or increase (D) in expression.
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perturbation of glutathione metabolism in response to
PB. Glutathione, glutamine, glycine and 5-oxo-proline
were all increased by PB exposure. Glutamine cysteine
ligase and glutathione reductase expression were
increased whereas glutamine synthetase expression was
decreased (figure 5C, table 3).
In the second approach, PLS was used to build regres-
sion models using the genomic data as the X block and
the normalized integrated areas of peaks corresponding
to individual metabolites as the Y variable. In many
cases an association was identified between PB induced
metabolic changes, metabolizing enzymes, and enzymes
involved with protecting against damage from oxidative
stress. Epoxide hydrolase, glutathione S-transferase, glu-
tathione reductase, cytochrome P450 2B2, cytochrome
P450 3A1, aldehyde dehydrogenase and UDP-
Figure 5 Integration of metabolomic and transcriptomic data using pathway mapping. Overlaid 1H-NMR spectra from day 14 samples
showing a dose dependent decrease in glycogen. A similar response is seen at all other time points (A). The glycogen synthesis pathway
demonstrating the correlation between transcriptional and metabolic changes. Hexokinase D, which is involved in control of the rate of
glycogen synthesis, is decreased indicating that the decrease in glycogen is due to decreased synthesis (B). Glutathione synthesis pathway. Due
to the extraction procedure, all glutathione detected is oxidized [38]. The increase in glutathione at days 1, 3 and 7 is likely to be due to an
increase in glutamate cysteine ligase expression (C). The key to the gene expression data is given in (D).
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glucuronosyltransferase were all induced by PB (table 3).
However, in the case of the increase in succinate
detected at each time point by both GC-MS and 1H-
NMR, the enzyme 5-aminolevulinate synthase (ALAS)
was found to correlate with hepatic succinate (figure 6A,
table 3). PLS also identified a correlation between
decreased plasma lipids and increased hepatic lipopro-
tein lipase (LPL) at days 7 and 14 (figure 6B) and con-
firmed the association between decreased in glucokinase
expression and decreased hepatic glycogen.
PB induced remodeling of lipids
GC-MS can only provide information about the total
fatty acid content of a sample, as information about the
lipid species which originally contained the fatty acids is
lost in the derivatisation procedure. Direct infusion ESI-
MS was used to profile intact lipid species and this tech-
nique identified many changes in response to PB (Addi-
tional file 3). Using a Perl script the data was
summarised in terms of a particular fatty acid or lipid
class that had changed in the multivariate analysis of the
data. In the presentation of the data it was not possible
to determine definitively the position of the double
bonds within given fatty acids by DI-ESI and so they are
defined in terms of the number of carbons and degree
of desaturation within the fatty acid, while presumed
names are given in parentheses. However, where assign-
ment was possible the name is given first.
Considering the free fatty acids, monoacylphospholi-
pids and diacylphospholipids together there was a
decrease in arachidonic acid (20:4) containing species at
all time points. GpEtn and GpCho species were
decreased at all time points and GpIns species were
increased at all time points (Figure 7). There were also
smaller decreases in species containing palmitic acid
(16:0) at days 7 and 14 and 22:6 (docosahexaenoic acid)
at days 3, 7 and 14 (Table 4). Many changes were
observed in the free fatty acids detected by direct infu-
sion ESI-MS. Stearic acid (18:0), oleic acid (18:1), 18:2,
20:3 and 20:5 (eicosapentaenoic acid) were all increased
by PB at all time points and arachidic acid (20:0), 22:0
and 22:4 were decreased at all time points. Despite
decreases in docosahexaenoic acid (22:6) and
Figure 6 Integration of metabolomic and transcriptomic data using PLS. Partial Least Squares (PLS) plots modeling changes in gene
expression associated with hepatic succinate at all time points (A) and CH2 of plasma lipids at days 7 and 14 (B), both measured by
1H-NMR
spectroscopy. The increase in succinate detected with increasing dose of PB correlates with an increase in 5-aminolevulinate synthase (ALAS)
expression and the decrease in plasma lipids detected with increasing dose of PB correlates with an increase in lipoprotein lipase (LPL)
expression. Control (filled sqaure), 50 ppm (open circle), 500 ppm (filled triangle), 1000 ppm (open square).
Waterman et al. BMC Genomics 2010, 11:9
http://www.biomedcentral.com/1471-2164/11/9
Page 9 of 17
arachidonic acid (20:4) in the total lipid content as mea-
sured by GC-MS and direct infusion ESI-MS, no signifi-
cant changes were seen for 22:6 (docosahexaenoic acid)
as the free fatty acid, and 20:4 (arachidonic acid) free
fatty acid was only significantly decreased on day 7.
However, decreases in diacylphospholipids containing
these fatty acids were observed (Table 4).
Direct infusion ESI-MS showed that species contain-
ing stearic acid (18:0) and palmitic acid (16:0) were gen-
erally increased by exposure to PB. The exceptions were
if they were in combination with a highly unsaturated
fatty acid (HUFA), especially 20:4 (arachidonic acid),
docosahexaenoic acid 22:6 (docosahexaenoic acid) or
22:5, when they tended to be decreased (Additional file
3. The class of phospholipid is also important, with
large changes in the proportions of different phospholi-
pid classes present in the liver being observed. There
was a general increase in GpIns species at all time
points (Figure 7). The only GpIns species that were
decreased were those containing arachidonic acid (20:4).
Most GpCho and GpEtn lipids were decreased across all
time points. Those GpCho and GpEtn species which
increased all contained stearic acid (18:0) (Additional
file 3).
Discussion
In this study we have examined the well characterized
non genotoxic carcinogen PB to investigate whether a
combined transcriptomic and metabolomic approach
could identify early stage mechanistic markers associated
with PB toxicity. To confirm that PB was producing the
effects reported previously, we measured a number of
classical parameters. Dietary administration of PB
resulted in an increase in relative liver weight (table 1),
centrilobular hypertrophy (figure 1) and a transient
increase in cell replication (table 1), all of which are in
accordance with the literature [3,4,9]. Both metabolo-
mics and transcriptomics identified changes in liver
Table 4 Number of occurrences of fatty acids and types of phospholipids in the lipid species significantly changed in
response to PB.
Day 3 Day 7 Day 14
Change with
increasing dose
of PB
Relative increase Relative decrease Relative increase Relative decrease Relative increase Relative decrease
14:0 0 (0/0/0) 0 (0/0/0) 0 (0/0/0) 0 (0/0/0) 0 (0/0/0) 1 (1/0/0)
16:0 11 (0/2/9) 7 (0/0/7) 3 (0/0/3) 18 (1/2/15) 10 (0/2/8) 18 (1/3/14)
16:1 2 (1/0/1) 0 (0/0/0) 0 (0/0/0) 1 (0/0/1) 0 (0/0/0) 3 (0/1/2)
17:0 0 (0/0/0) 2 (1/0/1) 0 (0/0/0) 2 (1/0/1) 0 (0/0/0) 0 (0/0/0)
18:0 19 (1/5/13) 12 (0/0/12) 18 (1/2/15) 13 (0/0/13) 20 (1/4/15) 15 (0/2/13)
18:1 6 (1/0/5) 5 (0/1/4) 4 (1/0/3) 5 (0/0/5) 4 (1/1/2) 7 (0/0/7)
18:2 7 (1/1/5) 2 (0/0/2) 6 (1/1/4) 6 (0/1/5) 5 (1/1/3) 5 (0/0/5)
18:3 1 (1/0/0) 0 (0/0/0) 0 (0/0/0) 1 (0/0/1) 0 (0/0/0) 1 (0/0/1)
19:0 0 (0/0/0) 1 (0/0/1) 0 (0/0/0) 1 (0/0/1) 0 (0/0/0) 0 (0/0/0)
20:0 0 (0/0/0) 1 (1/0/0) 0 (0/0/0) 1 (1/0/0) 0 (0/0/0) 1 (1/0/0)
20:1 1 (0/0/1) 0 (0/0/0) 1 (0/0/1) 1 (1/0/0) 1 (0/0/1) 2 (1/1/0)
20:2 1 (0/0/1) 2 (0/0/2) 1 (0/0/1) 2 (0/0/2) 1 (0/0/1) 3 (0/1/2)
20:3 2 (1/0/1) 3 (0/1/2) 4 (1/1/2) 4 (0/1/3) 3 (1/0/2) 3 (0/0/3)
20:4 0 (0/0/0) 11 (0/1/10) 1 (0/0/1) 15 (1/2/12) 4 (0/1/3) 9 (0/1/8)
20:5 2 (1/1/0) 2 (0/1/1) 1 (1/0/0) 2 (0/1/1) 2 (1/1/0) 2 (0/1/1)
22:0 0 (0/0/0) 1 (1/0/0) 0 (0/0/0) 1 (1/0/0) 0 (0/0/0) 1 (1/0/0)
22:1 0 (0/0/0) 1 (0/1/0) 0 (0/0/0) 0 (0/0/0) 0 (0/0/0) 1 (0/1/0)
22:4 1 (0/0/1) 1 (1/0/0) 1 (0/0/1) 1 (1/0/0) 2 (0/0/2) 1 (1/0/0)
22:5 2 (0/1/1) 3 (0/0/3) 2 (0/0/2) 3 (0/0/3) 3 (0/0/3) 3 (0/0/3)
22:6 2 (0/0/2) 5 (0/0/5) 3 (0/0/3) 5 (0/0/5) 4 (0/0/4) 6 (0/1/05)
GpIns 13 (0/4/9) 2 (0/0/2) 12 (0/3/9) 4 (0/1/3) 22 (0/5/17) 0 (0/0/0)
GpEtn 1 (0/0/1) 12 (0/2/10) 0 (0/0/0) 20 (0/3/17) 0 (0/0/0) 22 (0/5/17)
GpCho 4 (0/1/3) 9 (0/1/8) 5 (0/1/4) 9 (0/0/9) 3 (0/0/3) 12 (0/2/10)
GpGro 6 (0/0/6) 2 (0/0/2) 5 (0/0/5) 2 (0/0/2) 1 (0/0/1) 2 (0/0/2)
GpSer 0 (0/0/0) 2 (0/0/2) 0 (0/0/0) 2 (0/0/2) 0 (0/0/0) 2 (0/0/2)
GPA 5 (0/5/0) 3 (0/2/1) 0 (0/0/0) 4 (0/3/1) 6 (0/5/1) 5 (0/5/0)
Values are given as: total (fatty acid/monoacylphospholipids/diacylphospholipids). For example, at day 14 eighteen species containing 16:0 were decreased with
increasing dose of PB and this can be broken down into the free fatty acid, 3 monoacylphospholipids and 14 diacylphospholipids (1/3/14).
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metabolism after just one day of exposure to PB demon-
strating the sensitivity of this approach. Many metabo-
lites were identified as having altered in both liver and
plasma and in order to aid interpretation of these
results, metabolite and transcript data were integrated
highlighting several pathways which had been perturbed
by PB.
Hepatic glycogen
A large, dose dependent decrease in the amount of gly-
cogen in the livers of the animals given PB was observed
at all time points. Both direct mapping of changes in
gene expression onto the pathways and PLS regression
between transcriptional and metabolomic data identified
a decrease in glucokinase as being correlated with the
decrease in glycogen. Glucokinase catalyses the phos-
phorylation of glucose to glucose-6-phosphate and is
involved in controlling the rate of glycogen synthesis
and glycolysis [14]. This indicates that the decrease in
glycogen detected in the livers of animals exposed to PB
is a result of a decrease in glycogen synthesis, with this
previously being reported in vitro in isolated rat hepato-
cytes [15,16].
Hepatic glutathione
Hepatic glutathione was increased at days 1, 3 and 7 in
animals exposed to PB relative to control animals. This
was accompanied by an increase in the expression of
glutamate-cysteine ligase, the rate limiting enzyme in
the synthesis of glutathione, at days 1 and 3 in animals
exposed to PB. There are mixed reports as to whether
PB exposure increases glutathione [17-19], but in this
study the combined transcriptomic and metabolomic
data indicates PB increased hepatic glutathione by an
increase in synthesis. The majority of g-glutamylcysteine
is converted to glutathione by glutathione synthase, but
a small amount is converted to 5-oxoproline and
cysteine by g-glutamylcyclotransferase [20] (figure 5).
The proportions of g-glutamylcysteine being metabolized
by each path is controlled by the kinetics of the two
enzymes, and thus, the detected increase in 5-oxoproline
with PB dose suggests that flux through both pathways
has increased.
Glutathione reductase expression was increased for
animals in the mid and high dose groups at all time
points. This enzyme reduces oxidized glutathione back
to reduced glutathione in a NADPH dependent reaction
and provides an important anti-oxidative stress mechan-
ism in the liver. A number of mechanisms generate
NADPH for this conversion, including the conversion of
malate to pyruvate catalyzed by malic enzyme. The
expression of malic enzyme is highly correlated with
glutathione reductase expression (Pearson correlation
coefficient, r = 0.7), suggesting that the increase in malic
Figure 7 Lipidomic analysis of the liver tissue. Overlaying typical direct infusion ESI-MS spectra from the control, 50 ppm, 500 ppm and 1000
ppm groups at day 14 illustrates some of the changes occurring in the intact lipids. The 16:0 containing GpIns species are increased by
exposure to PB and GpEtn species containing 18:0 in combination with a HUFA are decreased by exposure to PB. The GpEtn species are
observed as adducts with an unknown species of mass 50.
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enzyme expression is due to increased demand for redu-
cing power which is associated with drug metabolism
and PB exposure [21].
Hepatic succinate
The increase in hepatic succinate caused by exposure to
PB could have been caused by alterations in a number
of different pathways, including increased TCA rate and
increased reducing potential demand by the liver cells.
However, using our combined metabolomic and tran-
scriptomic approach we demonstrate that succinate is
correlated with the increased expression of ALAS. This
enzyme catalyses the reaction between glycine and suc-
cinyl CoA to form 5-aminolevulinate, in the first com-
mitted step in heme biosynthesis [22] and PB induces
ALAS in isolated hepatocytes [23]. PB induces the
CYP2B family of cytochrome P450 enzymes and hence
the increase in heme biosynthesis induced by PB is con-
sistent with the heme requirements associated with
induction of cytochrome P450s [24].
Plasma lipids
Clinical biochemistry measurements showed a decrease
in plasma triglycerides in animals given the mid and
high doses of PB at day 14 and 1H-NMR of plasma also
showed a decrease in lipid resonances at days 7 and 14.
PLS demonstrated a correlation between the CH2 reso-
nance of plasma lipoproteins and LPL expression. LPL
is not normally expressed in liver tissue of adult rats.
However, it is expressed in the livers of neonatal rats
and its expression can be induced in adult rats, for
example by the PPAR agonist fenofibrate [25,26]. LPL is
found in the endothelial cells lining capillaries of tissues
and hydrolyses triglycerides from lipoproteins circulating
in the plasma to release fatty acids which can be taken
up by the tissue. Its induction in the liver of rats
exposed to PB may be responsible for the decrease in
plasma lipids, suggesting that the liver in these animals
has an increased demand for fatty acids, possibly due to
the proliferation in endoplasmic reticulum which is
known to be induced by PB [4,27,28].
High resolution 1H-NMR spectroscopic analysis of
plasma demonstrated differences in the lipoprotein frac-
tion with increasing PB dose. There is a subtle decrease
in chemical shift as the density of the lipoproteins
decreases and this affects the shape of the lipid peaks
detected in blood plasma [13]. At day 14, spectra from
rats exposed to PB demonstrated a shift in the terminal
methyl lipoprotein resonance to a lower chemical shift
reflecting an increase in high density lipoprotein and
decrease in low density lipoprotein as has been reported
in PB-exposed Sprague Dawley rats [29].
Lipid remodeling in the liver
The decrease in glycogen and increase in fatty acid
uptake in response to PB suggested that the proportions
of fat and carbohydrate in the liver were altered.
HRMAS 1H-NMR spectroscopy was used to study liver
tissue from day 14 and demonstrated a clear increase in
the ratio of lipid to carbohydrate in rats exposed to 500
and 1000 ppm PB. 1H-NMR showed a large, dose
dependent decrease in the levels of hepatic glucose and
glycogen at all time points. Expression of lipoprotein
lipase was increased in the high dose groups from day 3,
and this is also the time point at which changes in the
lipid species present were first detected by GC-MS.
Because of the relative low spinning speeds used during
HRMAS 1H NMR spectroscopy, the technique focuses
on the detection of lipids with some mobility, and hence
the increased lipid detected in the spectra reflect the
mobilization of triglyceride stores within the liver tissue.
Direct infusion mass spectrometry provided an impor-
tant tool for rationalising the total lipid changes
detected by GC-MS and HRMAS 1H NMR spectro-
scopy. The lipid changes were characterised by a global
increase in GpIns apart from those containing HUFAs,
while most GpCho and GpEtn species were decreased.
The synthesis of glycerophospholipids is complex. GpIns
and GpSer are both synthesized from CDP-DAG, while
GpEtn is synthesized from the decarboxylation of
GpSer. GpCho is synthesized either from GpSer by
sequential methylation by phosphatidylethanolamine N-
methyltransferase and S-adenosylmethionine or direct
from CDPcholine and DAG via CDP-choline:1,2-diacyl-
glycerol cholinephosphotransferase. In addition
CDPethanolamine and DAG are also precursors to
GpEth. In mammals this remodelling of glycerophop-
sholipids largely takes place in the ER [for a discussion
of these pathways see http://www.lipidlibrary.co.uk/
Lipids/complex.html]. PB induces proliferation of the
ER, and while the key enzymes involved in the synthesis
of GpIns, GpEtn and GpCho are all found within the
ER, in the present study PB selectively increased the
concentration of GpIns, while other phospholipids lar-
gely decreased in concentration. This suggests PB expo-
sure induces a remodelling of cellular lipids, which may
in turn relate to the biochemical changes associated
with pathological ER proliferation and the need to
synthesize particular phospholipids for membrane
synthesis.
Omic techniques
In this study the use of metabolomics and transcrip-
tomics has allowed the detection of many changes
occurring in response to PB using a small set of experi-
ments and without predefined hypotheses. This is the
first time that metabolomics and transcriptomics have
been used in combination to study the effects of PB
exposure and the published data available has been used
to validate the approach. This ability of omic techniques
to identify changes occurring across many metabolic
pathways and in different tissues and biofluids, without
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the need for a large number of targeted analyses, is one
of the technology’s key benefits and is well demon-
strated in this work. In addition, the transcriptomic data
strengthened the metabolomic data by improving the
interpretability of the metabolic changes. It was possible
to determine if a decrease in synthesis or an increase in
degradation was the cause of the decrease in the con-
centration of a metabolite (as in hepatic glycogen) and
the cause of changes in metabolites which lie on many
pathways were also identified (as in hepatic succinate).
The transcriptomic data is enhanced by metabolomic
data as changes in gene expression do not necessarily
imply changes in levels of enzymes and metabolite and
as not all proteins are under transcriptional control,
gene expression profiling can miss large changes which
can be detected with metabolomics [30,31].
Conclusions
In this study we have used a combined omic platform to
investigate early stage mechanistic biomarkers associated
with exposure to the classic rodent non-genotoxic carci-
nogen PB. The use of metabolomics and transcriptomics
in combination greatly enhanced the conclusions which
could be drawn from the dataset by aiding the interpre-
tation of metabolomic data and by linking changes in
gene expression to measured changes in metabolism.
Data available on this compound has allowed us to con-
firm our findings and interpretation, validating the use
of this approach for the study of less well characterized
compounds. Pathway perturbations included those asso-
ciated with glycogen synthesis, glycolysis, glutathione
metabolism and heme synthesis. Furthermore, the
approach was capable of identifying diverse mechanistic
responses, even for metabolites like succinate which
form a central hub in metabolism where a number of
pathways converge. This study has shown the sensitivity
of ‘omic technologies to identify many perturbations
without a predefined hypothesis, providing early stage
markers of the subsequent pathophysiology.
Methods
Animal handling and sample collection
All animal procedures conformed to the Home Office
(UK) guidelines for experimentation with animals and
were approved by local ethics committee at Syngenta.
Eighty nine week old male Fischer (F344) rats were ran-
domly divided into four groups of twenty animals (Addi-
tional file 4). Each group was exposed to a different
concentration (0, 50, 500 or 1000 ppm) of the sodium
salt of phenobarbital which was added to the standard
laboratory diet and milled to homogeneity. Animals were
fed ad lib throughout the study. Five animals from each
group were killed by exsanguination under halothane
anesthesia after 1, 3, 7 and 14 days of PB exposure. Blood
was collected into lithium heparin tubes, centrifuged at
2000 rpm for 10 minutes and the plasma separated for
clinical biochemistry. Plasma samples for metabolomic
analysis were stored at -80°C until analysis. Livers were
removed immediately and weighed. Samples of liver
(~150 mg) were taken from the left lateral lobe and snap
frozen in liquid nitrogen for genomic and metabolomic
analysis. Representative samples of liver for histopathol-
ogy were taken from the three main lobes, fixed for 48
hours in 10% neutral buffered formol saline and pro-
cessed to paraffin wax blocks. Sections of liver (4 μm)
were stained for ki67 by immunohistochemistry and the
labeled nuclei counted to produce a labeling index. A
sample of liver was taken from the right median lobe,
fixed in 3% glutaraldehyde in cacodylate buffer, pro-
cessed, embedded and examined by electron microscopy.
Materials
All chemicals were purchased from Sigma-Aldrich
(Poole, UK) with the exception of D2O, sodium-3-(tri-
methylsilyl)-2,2,3,3-tetradeuteriopropionate (TSP) and
N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA)
which were obtained from Goss Scientific (Great Bad-
dow, UK), Cambridge Isotope Laboratories (Andover,
MA) and Macherey-Nagel (Düren, Germany),
respectively.
Clinical chemistry
Plasma was analysed for the following parameters: total
protein, total bilirubin, creatine kinase activity, aspartate
aminotransferase activity, cholesterol, creatinine, albu-
min, alkaline phosphatase activity, gamma-glutamyl
transferase activity, triglycerides and glutamate dehydro-
genase using a Konelab clinical chemistry analyzer
(Thermo Scientific, Waltham, MA).
Tissue extraction
Tissue samples were extracted using methanol-chloro-
form as described by Le Belle et al [32]. Approximately
75 mg of frozen tissue was ground up with dry ice.
Methanol-chloroform solution (2:1, 600 μl) was added
and the samples were sonicated for 15 min. Chloro-
form-water (1:1, 400 μl) was added and the samples cen-
trifuged (20 min, 13 500 rpm). Aliquots of the resulting
aqueous and organic layers were taken for GC-MS,
LC-MS and 1H-NMR analysis. The aqueous fractions
were dried in an evacuated centrifuge. The organic frac-
tions and pellets were dried in a fume hood overnight.
High Resolution 1H-NMR spectroscopy
For analysis of liver tissue extracts, dried aqueous
extracts from 500 μl of the aqueous layer were dissolved
in phosphate buffered D2O (pH 7.0, 600 μl, 33 mM
Na2HPO4, 6.7 mM NaH2PO4, 0.1% sodium azide, 0.17
mM TSP). 1H-NMR spectra were acquired on a Bruker
DPX400 spectrometer operating at 400.13 Hz using a 5
mm probe. The standard “noesypr1d” pulse sequence
(Bruker Analytik GmbH, Germany) was used for solvent
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suppression (relaxation delay = 2 s, t1 = 3 μs, mixing
time = 150 ms, solvent presaturation applied during the
relaxation time and the mixing time). 128 transients
were collected into 16 K data points over a spectral
width of 12 ppm at 37°C. NMR free induction decays
(FIDs) were Fourier transformed with a line broadening
of 0.3 Hz. The spectra were phased, base line corrected,
referenced to TSP at 0.00 pm and integrated using ACD
labs NMR Processor (version 8, ACD, Toronto, Canada).
The spectra were integrated in 0.01 ppm buckets
between 0.20 and 9.95 ppm excluding the water region
(4.72-5.05 ppm). To account for concentration differ-
ences, the total integral of each spectrum was normal-
ized to 10000 and each peak represented as a ratio to
the normalized total integral. However, it became appar-
ent that there were very large differences in the amount
of glucose and glycogen in the liver extract samples and
so the spectra were also renormalized with the glucose
and glycogen resonances (3.35-4.05 ppm, 4.60-4.72 ppm,
5.20-5.55 ppm) excluded (Additional files 5).
For plasma analysis, plasma (250 μl) was added to 500
μl of deuterated acetonitrile/D2O (50:50). Samples were
mixed and centrifuged (12 000 rpm, 5 minutes) and 600
μl of supernatant taken for analysis. 1H-NMR spectra
were acquired on a Bruker DPX400 spectrometer operat-
ing at 400.13 Hz using a 5 mm probe. Samples were ana-
lysed using a Carr-Purcell-Meiboom-Gill (CPMG) pulse
sequence to suppress the contribution from large mole-
cules which also included a water pre-saturation regime.
128 transients were collected into 16 k data points across
a spectral width of 20 ppm at 37°C. The relaxation delay
was 2 s and the spin echo delay (d20) was 1 ms. 48 loops
(spin echoes) were used to give a total spin echo time of
96 ms. NMR FIDs were Fourier transformed with a line
broadening of 0.3 Hz. The spectra were phased, base line
corrected, referenced to the glucose doublet at 5.23 ppm
and integrated using ACD labs NMR Processor (version
8, ACD, Toronto, Canada). The spectra were integrated
in 0.02 ppm buckets between 0.60 and 8.00 ppm exclud-
ing the water region (4.68-5.15 ppm). To account for
concentration differences, the total integral of each spec-
trum was normalized to 10000 and each peak repre-
sented as a ratio to the normalized total integral.
For HRMAS 1H NMR experiments approximately 15
mg of tissue was soaked in D2O with 10 mM TSP then
placed in a 4 mm diameter zirconium oxide rotor for
analysis. The sample was packed into a homogeneous
ball of 30 μl volume using a Teflon spacer. HRMAS
experiments were conducted on a Bruker AVANCE II+
spectrometer operating at 500.13 MHz for the 1H fre-
quency and using a high resolution 4 mm MAS probe.
Samples were spun at a frequency of 4500 Hz at a tem-
perature of 27°C. A “noesypr1d” pulse sequence was
used (relaxation delay = 2.5 s, t1 = 4 μs, mixing time =
50 ms, solvent presaturation applied during the relaxa-
tion time and the mixing time). 64 transients were col-
lected into 32 k data points across a spectral width of
16 ppm. FIDs were Fourier transformed with a line
broadening of 1 Hz The spectra were phased, base line
corrected, referenced to TSP at 0.00 pm and integrated
using ACD labs NMR Processor (version 8, ACD, Tor-
onto, Canada). The spectra were integrated in 0.04 ppm
buckets between 0.50 and 5.60 ppm, excluding the
water region (4.75-5.00 ppm).
Gas Chromatography Mass Spectrometry (GC-MS)
The dried aqueous extracts from 100 μl of the aqueous
phase of the extraction mixture were derivatised with
methoxyamine hydrochloride in pyridine (20 mg ml-1,
30 μl, 17 hr, 22°C) and silylated using MSTFA (30 μl, 1
hr, 22°C) [33]. 50 μl of the derivatised sample was added
to 200 μl hexane prior to analysis (Additional files 5).
The dried organic fraction was treated with a methy-
lating reagent which formed the fatty acid methyl esters
of carboxylic acids. Chloroform-methanol (1:1, 750 μl)
and boron trifluoride in methanol (~10%, 125 μl) were
added to the extract and the samples heated to 80°C for
90 minutes. Deionized water (300 μl) and hexane (600
μl) were added, the samples vortex mixed and the lower
layer was removed and dried. The dried samples were
reconstituted in 150 μl hexane prior to analysis [34]
(Additional files 5).
GC-MS analysis was carried out using a Thermo Elec-
tron Trace GC Ultra coupled to a Thermo Electron
DSQ single quadrupole mass spectrometer. For all ana-
lyses the injector temperature was 230°C. Helium was
used as the carrier gas and maintained at a constant
flow of 1.2 ml min-1. The MS was operated in full scan
mode with 3 scans s-1 across a range of 50-650 m/z.
Derivatised aqueous extracts were analysed using a 30
m × 0.25 mm ID × 0.25 μm df 5%-phenyl-95%-
dimethylpolysiloxane column. 1 μl derivatised sample
was injected splitless. The initial column temperature of
70°C was held for 2 minutes then the temperature was
ramped at 5°C min-1 to 310°C and this temperature was
held for 20 minutes.
Derivatised organic extracts were analysed on a 30 m
× 0.25 mm × 0.25 μm 100% polyethylene glycol column.
2 μl derivatised sample was injected with a split ratio of
20:1. The initial column temperature of 60°C was held
for 2 min and then the temperature was ramped at 6°C
min-1 to 230°C and this temperature was held for 7 min.
GC-MS data was analyzed using Qual Browser version
1.4 (Thermo Electron Corporation). Peaks were inte-
grated individually and the total integrated peak area of
each spectrum normalized to 10000.
Univariate statistical analysis
Liver and body weight, clinical chemistry, food con-
sumption and Ki67 staining were analysed by 1-way
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analysis of variance to identify differences between the
dose groups. Dunnett’s multiple comparison test was
then used to identify which of the treatment group
means were significantly different to the control group
mean [35].
Multivariate statistical analysis
Normalized data was imported into SIMCA-P+ (v. 11,
Umetrics, Umeå, Sweden) for multivariate statistical
analysis. The data was mean centered and scaled. Scal-
ing is necessary so that high concentration metabolites
do not dominate the models. NMR data was Pareto
scaled to suppress the contribution from regions of the
spectra containing no peaks. Since in the GC-MS analy-
sis only identified peaks were used, GC-MS data was
scaled to unit variance. Initially, PCA models were built
to look for clustering and identify outliers, and then PLS
was applied to improve the separation and look for
changes correlated with increasing dose of PB. These
are essentially data reduction methods whereby the
major variation in the dataset is summarized in new
variables known as components. Thus, a dataset which
has thousands of variable can be summarized in typi-
cally fewer than ten new components [36]. PCA is an
unsupervised technique which identifies the major
sources of variation in the dataset. PLS is a supervised
technique which identifies variation in the dataset (the
X-block) which correlates with a specific variable (the
Y-variable), in this study the dose of PB. R2 and Q2
values were used to assess the amount of variation
represented by the principal components and robustness
of the model, respectively. To prevent over fitting, the
predictive capability of the models was checked by sam-
ples from the dataset, building a model and then pre-
dicting the dose for the omitted samples. The validate
function in SIMCA was also used to check the models.
This function randomly permutes the Y variables and
calculates the R2 and Q2. As the similarity between the
actual doses and the permuted doses falls, so should the
R2 and Q2 values.
Gene expression analysis
Total RNA was isolated from 150 mg of tissue using a
midi column according to the manufactures instructions
(Qiagen; West Sussex, UK). RNA quality and concentra-
tion were determined using an Agilent Bioanalyzer and
samples were repurified if the calculated RNA Integrity
Number was below 7. Purified RNA was converted to
complementary DNA, amplified and then converted to
biotin-labeled complementary RNA using Affymetrix
GeneChip 3’ Amplification reagents (Affymetrix, High
Wycombe). 15 ug was hybridized to Affymetrix Rat
Expression RG-230 v2 GeneChips as described in the
Affymetrix GeneChip Expression Analysis Technical
Manual http://www.affymetrix.com/support/technical/
manual/expression.manual.affx. The probe arrays were
scanned and the probeset intensities were combined and
averaged using Microarray Suite 5.0 (Affymetrix). The
mean of each array was globally normalized to 500.
Data were imported into GeneSpring GX version 7 and
the following normalizations performed: data transfor-
mation to set expression values below 0.01 to 0.01; per
gene normalization, where the signal strength of each
gene is normalized to the median of its signal strength
in all samples. The microarray data is available at Gene
Expression Omnibus (GSE18753).
The probesets on the array were then analyzed by a
number of filters and statistical tests. Firstly to remove
probesets for genes without detectable expression: genes
that did not have at least 3 present flags were excluded
and genes that had an expression value of less than 90
in at least 3 samples were also excluded. To ensure
robust detection of any differentially expressed genes
any probeset that showed less than a 1.5-fold change in
expression relative to its time-matched control were also
excluded. To detect significant changes in expression
levels a 2-way analysis of variance was performed on the
filtered gene list (using a Benjamini and Hochberg false
discovery rate of < 0.05) on time and treatment. Ratios
of changes in gene expression were calculated by nor-
malizing each treated sample to the median value of the
time-matched control. These ratios were used for hier-
archical clustering of the differentially expressed genes
using the Pearson correlation coefficient. Differentially
expressed genes were functionally categorized using
their Gene Ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways annotations
using GeneSpring GX. GO over-representation analysis
was performed using the GeneSpring GX GO browser.
The significance of a Gene Ontology Biological Process
being over-represented in a gene list relative to the
annotations on the chip was assessed using a hypergeo-
metric p-value < 0.05 without multiple testing correc-
tions. KEGG pathway over-representation was
performed using the GeneSpring GX script “SG3b-1
Find genes in a GL present in PATHWAYS” contained
within the Bioscript Library 2.2 (Agilent). A pathway
needed to have at least 3 differentially expressed genes
and a p < 0.05 to be included in the analysis [37].
Integration of metabolomic and genomic data
Two approaches were taken to integrate the data gener-
ated by metabolomic and genomic analyses. Firstly, sig-
nificant changes in gene expression were mapped on to
Kyoto Encyclopedia of Genes and Genomes (KEGG)
metabolic pathways using GeneSpring (Agilent Technol-
ogies, Santa Clara, CA). This allowed the identification
of pathways where both the concentrations of tran-
scripts and metabolites were altered.
In the second approach, PLS was used to build regres-
sion models using the genomic data as the X-block and
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the normalized integrated areas of peaks corresponding
to individual metabolites identified which were altered
by PB exposure as the Y-variable. PLS is an extension of
PCA where a projection model is developed predicting
Y from X via scores of X, and is a generalized multiple
regression method suitable for multiple collinear X and
Y variables. This method identifies changes in the gene
expression data which correlate with changes in the
concentration of a particular metabolite and is particu-
larly advantageous when investigating changes in meta-
bolites which lie on many pathways. Correlations were
identified by the examination of the X and Y compo-
nents of the first component of the PLS model. In addi-
tion, the goodness of fit (Q2) of the model was
evaluated by excluding every 7th sample as part of a
leave one out cross validation process. Q2 is defined as
the fraction of the total variation of the X matrix that
can be predicted by a component as estimated by cross-
validation and Q2 = (1.0-PRESS/SS) where PRESS is the
predicted error sum of squares which is the squared dif-
ference between observed Y and predicted Y and SS is
the residual sum of squares of the previous component.
The loading plots for the PLS model show the correla-
tion between the X variables, or their residuals in subse-
quent dimensions, in the first dimension, and the Y
variables (or Y residuals scores in subsequent dimen-
sions). The weights are selected so as to maximize the
covariance between the X matrix and Y block. The load-
ings were ranked according to magnitude and in this
way, the transcripts which were most highly correlated
with changes in the concentration of a particular meta-
bolite could be identified. Correlates were considered as
significant if Q2>0.40 and the procedure passed the
cross-validation routine in Simca-P+ whereby the real
Q2 was calculated to be greater than 30 models gener-
ated using a random permutation of the Y scores.
Additional file 1: Metabolite changes in response to increasing
dose of phenobarbital. Metabolite changes in liver and plasma in
response to increasing dose of PB as detected by 1H-NMR spectroscopy
and GC-MS across the time course of the study.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-9-
S1.DOCX ]
Additional file 2: Pathways identified as perturbed by
transcriptomic analysis. Pathways and biological processes which are
over represented in the set of genes whose expression is altered by
phenobarbital. Genes are grouped by temporal expression profile as
described Figure 4.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-9-
S2.DOCX ]
Additional file 3: Remodelling of the lipid profile of liver tissue
following PB treatment. Changes in intact phospholipids in response to
increasing dose of PB as detected by negative mode direct infusion ESI-
MS of extracts from liver tissue.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-9-
S3.DOC ]
Additional file 4: Study design for animal experiment. This table
depicts the animal numbers used in the design of the study.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-9-
S4.XLS ]
Additional file 5: Metabolomics Standards Initiative Compliant
Metadata. The excel spread sheets contain all the metabolomics data
collected by NMR spectroscopy and GC-MS of fatty acid methyl esters
according to the Standard reporting requirements for biological samples
in metabolomics experiments: mammalian/in vivo experiments.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2164-11-9-
S5.XLS ]
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